Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced Hormone Receptor-Positive Breast Carcinoma”

306 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 306 results

Large-scale testing (Phase 3)Study completedNCT00390455
What this trial is testing

Fulvestrant With or Without Lapatinib in Treating Postmenopausal Women With Stage III or Stage IV Breast Cancer That is Hormone Receptor-Positive

Who this might be right for
Estrogen Receptor PositiveHER2 Positive Breast CarcinomaHER2/Neu Negative+5 more
National Cancer Institute (NCI) 295
Testing effectiveness (Phase 2)UnknownNCT04318223
What this trial is testing

Palbociclib Plus Fulvestrant in Women With Hormone Receptor Positive and Human Epidermal Growth Factor Receptor Type 2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination With Hormonal Therapy

Who this might be right for
Metastatic Breast CancerLocally Advanced Breast Cancer
Consorzio Oncotech 168
Early research (Phase 1)Looking for participantsNCT07524322
What this trial is testing

Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

Who this might be right for
Breast CancerOvarian CancerEndometrial Cancer+6 more
Regor Pharmaceuticals Inc. 63
Large-scale testing (Phase 3)Ended earlyNCT06038539
What this trial is testing

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Who this might be right for
HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients
Biocon Biologics UK Ltd 55
Testing effectiveness (Phase 2)Ended earlyNCT02395627
What this trial is testing

Reversing Therapy Resistance With Epigenetic-Immune Modification

Who this might be right for
Breast Neoplasms
University of California, San Francisco 38
Not applicableUnknownNCT05814224
What this trial is testing

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA

Who this might be right for
Hormone Receptor Positive Breast CarcinomaBreast NeoplasmsNeoplasms, Breast+4 more
Centro di Riferimento Oncologico - Aviano 164
Testing effectiveness (Phase 2)Active Not RecruitingNCT03944434
What this trial is testing

FACILE: FeAsibility of First-line RiboCIclib in OLdEr Patients with Advanced Breast Cancer

Who this might be right for
Breast Cancer
Fondazione Sandro Pitigliani 116
Very early researchWithdrawnNCT04088032
What this trial is testing

Neoadjuvant Study of Abemaciclib, Durvalumab, and an Aromatase Inhibitor Early Stage Breast Cancer

Who this might be right for
Breast Cancer FemaleLocally Advanced Breast CancerHormone Receptor Positive Malignant Neoplasm of Breast
Alison Stopeck
Post-approval studies (Phase 4)WithdrawnNCT03988114
What this trial is testing

Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company
Early research (Phase 1)Study completedNCT02586675
What this trial is testing

TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer

Who this might be right for
Breast CancerBreast Cancer - FemaleBreast Cancer - Male
H. Lee Moffitt Cancer Center and Research Institute 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT05226871
What this trial is testing

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Who this might be right for
Breast CancerHead and Neck Cancer
Pfizer 35
Early research (Phase 1)Study completedNCT02219789
What this trial is testing

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Who this might be right for
Estrogen Receptor PositiveProgesterone Receptor PositiveRecurrent Breast Carcinoma+3 more
Mayo Clinic 10
Large-scale testing (Phase 3)Active Not RecruitingNCT02115282
What this trial is testing

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

Who this might be right for
Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Breast Adenocarcinoma+4 more
National Cancer Institute (NCI) 608
Large-scale testing (Phase 3)UnknownNCT03538171
What this trial is testing

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Advanced Breast Cancer
Taizhou EOC Pharma Co., Ltd. 375
Early research (Phase 1)Study completedNCT02088684
What this trial is testing

Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 70
Testing effectiveness (Phase 2)UnknownNCT02983071
What this trial is testing

G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Carcinoma, Ductal, BreastBreast CancerBreast Neoplasm
G1 Therapeutics, Inc. 102
Testing effectiveness (Phase 2)UnknownNCT05806671
What this trial is testing

Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy

Who this might be right for
Breast Cancer
Tianjin Medical University Cancer Institute and Hospital 30
Early research (Phase 1)Study completedNCT01576666
What this trial is testing

Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors

Who this might be right for
Dose EscalationSafetyPreliminary Efficacy+9 more
Novartis Pharmaceuticals 120
Not applicableLooking for participantsNCT06123988
What this trial is testing

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

Who this might be right for
HER2-positive Breast CancerAdvanced Breast Cancer
University of Miami 260
Early research (Phase 1)Study completedNCT01870505
What this trial is testing

BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

Who this might be right for
Metastatic or Locally-advanced Unresectable Breast Cancer
Memorial Sloan Kettering Cancer Center 52
Load More Results